Gross Profit Comparison: Amneal Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. Trends

Amneal vs. Supernus: A Decade of Profit Trends

__timestampAmneal Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 2014449634000116287000
Thursday, January 1, 2015499226000136004000
Friday, January 1, 2016597455000203017000
Sunday, January 1, 2017526178000287023000
Monday, January 1, 2018716403000393541000
Tuesday, January 1, 2019352997000376095000
Wednesday, January 1, 2020628393000467938000
Friday, January 1, 2021768973000504714000
Saturday, January 1, 2022784708000580017000
Sunday, January 1, 2023820565000523742000
Loading chart...

Unleashing the power of data

A Tale of Two Pharmaceutical Giants: Amneal vs. Supernus

In the ever-evolving pharmaceutical landscape, Amneal Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have showcased intriguing trends in their gross profit margins over the past decade. From 2014 to 2023, Amneal's gross profit surged by approximately 82%, reflecting its strategic growth and market adaptability. In contrast, Supernus experienced a robust 350% increase, highlighting its aggressive expansion and innovation-driven approach.

Key Insights

  • 2018 Milestone: Amneal's gross profit peaked at 716 million, marking a pivotal year in its financial journey.
  • Supernus' Steady Climb: By 2023, Supernus reached a gross profit of 524 million, underscoring its consistent upward trajectory.

These trends not only reflect the companies' financial health but also their strategic positioning in the competitive pharmaceutical sector. As the industry continues to evolve, these giants remain at the forefront, setting benchmarks for profitability and growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025